Advertisement

Access to Affordable Breast Cancer Care in Eastern Europe

  • Alexandru Eniu
  • Nicoleta Antone
Global Breast Cancer (BO Anderson and C Duggan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Global Breast Cancer

Abstract

Purpose of Review

The majority of Central and Eastern European (CEE) countries report inferior breast cancer survival rates compared with Western European countries. We review limitations in access to screening programs, surgery, radiotherapy, pathology, palliative care, and antineoplastic medicines as potential explanations for these disparities.

Recent Findings

Most CEE countries do not have the quality and quantity of radiotherapy needed to adequately service the population. Surgical services are widely accessible, but sentinel node biopsy is not universally available. There are important limitations for CEE patients in accessing high-quality pathology. Many patients living with advanced cancer are in dire need of palliation services. Important inequalities exist in availability and patient costs, especially for newer, more expensive drugs, across Europe, while drug shortages affect several “essential,” old, and inexpensive drugs.

Summary

Improvements in radiotherapy, surgery, and pathology and access to medicines are needed, together with the provision of trained health care professionals.

Keywords

Breast cancer Eastern Europe Limited resources 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, et al. Cancer survival in Europe 1999–2007 by country and age: EUROCARE-5 2014;15(1):23–34. Doi: 10.1016/S1470-2045(13)70546-1.Google Scholar
  2. 2.
    Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol. 2008 Jun;19(6):1187–94.  https://doi.org/10.1093/annonc/mdn025. CrossRefPubMedGoogle Scholar
  3. 3.
    Esiashvili N. Radiation oncology in the developing economies of central and Eastern Europe. Semin Radiat Oncol. 2017;27(2):150–7.  https://doi.org/10.1016/j.semradonc.2017.01.001.CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868–74.  https://doi.org/10.1200/JCO.2009.23.1183.CrossRefPubMedGoogle Scholar
  6. 6.
    Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16(11):1193–224.  https://doi.org/10.1016/S1470-2045(15)00223-5.CrossRefPubMedGoogle Scholar
  7. 7.
    Biganzoli, et al. Quality indicators in breast cancer care: An update from the EUSOMA working group. Eur J Cancer. 2017;86:59–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Luengo-Fernandez R, Leal J, Gray A, Sullivan R, et al. Economic burden of cancer across the European Union: a population-based cost analysis. RLancet Oncol. 2013 Nov;14(12):1165–74.  https://doi.org/10.1016/S1470-2045(13)70442-X.CrossRefGoogle Scholar
  9. 9.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.  https://doi.org/10.1016/j.ejca.2012.12.027.; EUCAN national estimates (eco.iarc.fr/eucan).CrossRefPubMedGoogle Scholar
  10. 10.
    European commission. Cancer screening in the European Union report on the implementation of the council recommendation on cancer screening. Reprint May 2017.Google Scholar
  11. 11.
    Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, et al. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. Eur J Cancer. 2014 Dec;50(18):3089–97.  https://doi.org/10.1016/j.ejca.2014.09.011.CrossRefPubMedGoogle Scholar
  12. 12.
    Chaker L, Falla A, van der Lee SJ, et al. The global impact of non-communicable diseases on macro-economic productivity: a systematic review. Eur J Epidemiol. 2015;30:357–95.  https://doi.org/10.1007/s10654-015-0026-5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Josip Banovich. Breast specialized surgeon from KBC split, Krizine, Croatia. Personal communication.Google Scholar
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
    Dare AJ, Anderson BO, Sullivan R, Pramesh CS, Yip CH, Ilbawi A, et al. Surgical services for cancer care. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer volume, disease control priorities in developing countries. 3rd ed. Washington, DC: World Bank; 2015. http://dcp-3.org/chapter/1536/surgical-services-cancer-care.Google Scholar
  19. 19.
    Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015 Sep;16(10):1153–86.  https://doi.org/10.1016/S1470-2045(15)00222-3.CrossRefPubMedGoogle Scholar
  20. 20.
    Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol. 2015;116:45–50.  https://doi.org/10.1016/j.radonc.2015.04.021. published online May 19CrossRefPubMedGoogle Scholar
  22. 22.
    Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, et al. The optimal utilization proportion of external beam radiotherapy in European countries:an ESTRO-HERO analysis. Radiother Oncol. 2015;116:38–44.  https://doi.org/10.1016/j.radonc.2015.04.018. published online May 14CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scalliet P, Boniol M, et al. Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol. 2013;14:e79–86.  https://doi.org/10.1016/S1470-2045(12)70556-9.CrossRefPubMedGoogle Scholar
  24. 24.
    Samiei M. Challenges of making radiotherapy accessible in developing countries. http://globalhealthdynamics.co.uk/cc2013/wp-content/uploads/2013/04/83-96-Samiei-varian-tpage-incld-Tpage_2012.pdf.
  25. 25.
    Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, et al. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer. 2008;113(suppl):2257–68.  https://doi.org/10.1002/cncr.23844.PubMedGoogle Scholar
  26. 26.
    Shyyan R, Masood S, Badwe RA, Errico KM, Liberman L, Ozmen V, et al. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J. 2006;12(suppl 1):S27–37.CrossRefPubMedGoogle Scholar
  27. 27.
    Soofi Y, Khoury T. Inter-institutional pathology consultation: the importance of breast pathology subspecialization in a setting of tertiary cancer center. Breast J. 2015;21:337–44.  https://doi.org/10.1111/tbj.12420.CrossRefPubMedGoogle Scholar
  28. 28.
    Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, et al. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open. 2014;4:e004652.  https://doi.org/10.1136/bmjopen-2013-004652.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Eniu A, Pop L, Stoian A, Dronca E, Matei R, Ligtenberg M, et al. Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: first report on founder mutations in Romanians. Ann Oncol. 2017;Volume 28(suppl_5):mdx362.047.  https://doi.org/10.1093/annonc/mdx362.047.CrossRefGoogle Scholar
  30. 30.
    Connor SR, Bermedo MCS, editors. Global atlas of palliative care at the end of life. Geneva: World Health Organization; 2014. http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf Google Scholar
  31. 31.
    Mosoiu D, Eniu A. Barriers towards establishing palliative care in Eastern Europe and prospects for improvement in the future: Romania as an example. In: Silberman M, editors. Palliative Care: Perspectives, Practices and Impact on Quality of Life, Nova Science Publishers, 2017, ISBN: 978-1-53612-084-4).Google Scholar
  32. 32.
    T. Brodowicz, I. Steiner, S. Beslija, T. E. Ciuleanu, M. Inbar, M. Krzakowski, Z. Kahan, V. et al, Time inclusion between final protocol approval and inclusion of the first patient into randomized clinical trials performed by the Central European Cooperative Oncology Group (CECOG): a 10 years experience, Journal of Clinical Oncology200927:15S, 6546–654621.1 Ramya Ramaswami, Eduardo Paulino, Adriana Barrichello, Angelica Nogueira-Rodrigues, Alexandra Bukowski, Jessica St. Louis, Paul E. Goss, Disparities in Breast, Lung, and Cervical Cancer Trials Worldwide, Journal of Global Oncology, no. 4 (May 2018) 1–11. https://doi.org/10.1200/JGO.17.00226.
  33. 33.
    Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, et al. Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. Oncologist. 2013 Feb;18(2):134–40.  https://doi.org/10.1634/theoncologist.2012-0342.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ramaswami R, Paulino E, Barrichello A, Nogueira-Rodrigues A, Bukowski A, Louis JSt., Goss PE, Disparities in breast, lung, and cervical cancer trials worldwide. J Glob Oncol. 4:1–11.  https://doi.org/10.1200/JGO.17.00226.
  35. 35.
    Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016 Aug;27(8):1423–43.  https://doi.org/10.1093/annonc/mdw213.CrossRefPubMedGoogle Scholar
  36. 36.
    Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO international consortium study on the availability, out-of-pocket costs and accessibility of anti-neoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28:2633–47.  https://doi.org/10.1093/annonc/mdx521.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
  38. 38.
    Cancer medicines shortages in Europe, Policy recommendations to prevent and manage shortages. Economist Intelligence Unit (EIU) Healthcare study. available at http://www.eiu.com/graphics/marketing/pdf/ESMO-Cancer-medicines-shortages.pdf (accessed 27 Apr 2018).Google Scholar
  39. 39.
  40. 40.
  41. 41.
    Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. ESMO-magnitude of clinical benefit scale. Ann Oncol. 2015;26(8):1547–73.  https://doi.org/10.1093/annonc/mdv249.CrossRefPubMedGoogle Scholar
  42. 42.
    Anderson BO, Duggan C. Resource-stratified guidelines for cancer management: correction and commentary. J Glob Oncol. 2017;3:84–8.CrossRefPubMedGoogle Scholar
  43. 43.
    World Health Organization: The seventieth world health assembly. Cancer prevention and control in the context of an integrated approach, in The seventieth world health assembly (ed): A70/a/CONF./9. Geneva, 2017.Google Scholar
  44. 44.
    Carlson RW, Scavone J, Koh W-J, et al: NCCN framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw:in press, 2016.Google Scholar
  45. 45.
    Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017 Oct 1;28(10):2340–66.  https://doi.org/10.1093/annonc/mdx310.CrossRefPubMedGoogle Scholar
  46. 46.
    Vivot A, Jacot J, Zeitoun J-D, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol.  https://doi.org/10.1093/annonc/mdx053.
  47. 47.
    Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, et al. Breast health global initiative treatment panel. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008;113(8 Suppl):2269–81.  https://doi.org/10.1002/cncr.23843. CrossRefPubMedGoogle Scholar
  48. 48.
    Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol. 2011;29(2):174–85.  https://doi.org/10.1200/JCO.2010.31.9624.CrossRefPubMedGoogle Scholar
  49. 49.
    Wasserstein RL, Lazar NA. The ASA's statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129–33.  https://doi.org/10.1080/00031305.2016.1154108.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Breast TumorsCancer Institute “Ion Chiricuta”Cluj-NapocaRomania

Personalised recommendations